Portfolio 1
| Date | Name | Website | Total Raised | Location |
| 13.06.2022 | Elektrofi | elektrofi.com | $40M | United Sta... |
Mentions in press and media 8
| Date | Title | Description |
| 28.05.2024 | Johnson & Johnson acquires Numab spin-off for USD 1.25 billion | Numab Therapeutics AG based in Horgen (ZH) is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Johnson & Johnson will acquire global rights to Numabs lead molecule NM26, a Phase 2-ready investigatio... |
| 30.06.2023 | CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P. | - |
| 24.02.2023 | ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M | ASLAN to receive $20 million in financing with the potential to receive up to an additional $80 million for an aggregate of $100 million to continue advancing the clinical development of eblasakimab and farudodstat ASLAN’s expected cash run... |
| 24.02.2023 | ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M | - |
| 20.05.2021 | Numab Therapeutics Completes CHF 100 Million Series C Financing | |
| 20.05.2021 | Numab Therapeutics Completes CHF 100 Million Series C Financing | Numab Therapeutics aims to write the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. Its lead product was designed to balance potent anti-tumor immunity wit... |
| 11.05.2021 | A newly launched biotech start-up with impressive study results in The Lancet | Zug-based MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on creating therapies for inflammatory skin and joint diseases. Full results of a Phase 2b study of its Tri-specific “Nanobody” Sonelokimab were publish... |
| 11.05.2021 | A newly launched biotech start-up with impressive study results in The Lancet |